Gilead Sciences (GILD) Tops Q4 EPS by 22c; Approves Dividend Program, $15B Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Gilead Sciences (GILD) Commentary Does Little to Quell Fears But Stock Undervalued - Cowen
February 4, 2015 9:08 AM ESTCowen analyst Phil Nadeau maintained an Outperform rating and $125 price target on Gilead Sciences (NASDAQ: GILD) following solid Q4 results, in-line 2015 sales guidance but commentary that did little to quell fears.
Nadeau commented, "GILD reported Q4:14 HCV sales ahead of consensus, and provided... More
Gilead (GILD) Price Target Lowered to $118 at RBC Capital
February 4, 2015 9:04 AM ESTRBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $118.00 (from $125.00). The change follows Q4 results. Overall analyst Michael J. Yee thinks the stock is cheap, with lots of optionality.
" ...GILD spooked investors with 2015 HCV guidance of "gross-to-net" rebates of 46%, which was higher than consensus 30%+, implying net pricing lower and competitive deals to... More
Gilead Sciences (GILD) PT Trimmed to $116 at Piper Jaffray as Guidance was a Letdown
February 4, 2015 8:54 AM ESTPiper Jaffray analyst Joshua Schimmer weighed in on Gilead Sciences (NASDAQ: GILD) following solid Q4 results but noted guidance was a letdown. The firm maintained an Overweight rating and trimmed its price target to $116.00 (from $120.00).
Schimmer commented, "GILD reported a solid 4Q... More
Goldman Sachs Lowers Its Price Target on Gilead (GILD) to $85
February 4, 2015 8:26 AM ESTGoldman Sachs maintained a Neutral rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $85.00 (from $96.00). The change follows Q4 results. Analyst Terence Flynn noted HepC pricing dynamics surprised to the downside.
"GILD guided to a 46% gross-to-net on US hepC pricing in 2015 (vs.... More
Gilead Sciences (GILD) Estimates Trimmed at Needham & Company Post Q4; 'Buy' Maintained
February 4, 2015 8:16 AM ESTNeedham & Company analyst Alan Carr lowered estimates on Gilead Sciences (NASDAQ: GILD) following Q4 results but maintained a Buy rating and price target of $120.
Carr commented, "4Q14 Sovaldi sales were $1.73B, compared to our $1.90B estimate. Ex-U.S. sales were lower than... More
Gilead Sciences (GILD) PT Trimmed to $141 at Nomura Posts Q4
February 4, 2015 7:40 AM ESTNomura Securities analyst M. Ian Somaiya trimmed his price target on Buy-rated Gilead Sciences (NASDAQ: GILD) to $141.00 (from $146.00) following results after the close.
Somaiya commented, "We expect the shock of aggressive discounting by Gilead (46% vs. our 20% estimate) on its HCV drugs to lead to... More
Baird 'Incrementally Negative' on Gilead (GILD) Following Call
February 4, 2015 7:11 AM ESTBaird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) saying they are incrementally negative following 4Q14 earnings call.
Skorney commented, "A sizeable beat, new dividend and massive share buyback program aren't enough to offset the disappointment in... More
Gilead Sciences (GILD) Approves Dividend Program; Adds $15B to Buyback Authorization
February 3, 2015 4:07 PM ESTGilead Sciences (NASDAQ: GILD) announced that the companys Board of Directors has authorized a dividend program under which the company intends to pay quarterly dividends of $0.43 per share, beginning in the second quarter of 2015, subject to quarterly declarations by the Board of Directors.
The Board of Directors also approved the... More
